JAK1 and Alzheimer disease: Upadacitinib also selectively and reversibly inhibits JAK1, and it was approved for the treatment of moderate-to-severe AD across two dosages (15 mg and 30 mg), after being evaluated in several phase-III clinical trials, demonstrating superiority over both the placebo and dupilumab [21,22,23].